Node Positive Bladder Cancer Can Be Treated With Intensity-Modulated Radiotherapy (IMRT)
According to a new clinical trial, targeted forms of radiotherapy
can effectively treat bladder cancer
which has spread to the lymph nodes
of the pelvis. This form of cancer
, known as node
positive bladder cancer
has a particularly poor prognosis and hasn’t usually been treated with radiotherapy
. Patients are traditionally offered palliative treatment to manage their pain and other symptoms instead.
Medical scientists at The Institute of Cancer Research, London, in conjunction with researchers and clinicians at The Royal Marsden NHS Foundation Trust, conducted a phase II clinical trial assessing the use of radiotherapy
in patients with bladder cancer
which had spread to the pelvic lymph nodes
Individuals whose cancer
had not yet spread to the pelvic lymph node
s, but who were considered to have cancer at a high risk of spreading to the nodes
, were also included in the study.
The research sought to assess the use of a type of radiotherapy
called intensity-modulated radiotherapy
) to treat the bladder and pelvic lymph nodes
and observe any toxic effects that resulted from the treatment.
is a type of radiotherapy
in which the shape of the radiation
beam is guided to fit closely around the shape of the tumour, while the machine moves around the patient’s body.
Certain patients who have chemotherapy and surgery to remove their bladder
and pelvic lymph nodes
do achieve control of their disease, but radiotherapy
is not typically offered as part of the treatment plan.
There are many concerns around the use of radiotherapy
in bladder cancers
centre on the risks involved in the toxicity caused by treatment of the whole pelvic area with radiotherapy,
which can cause symptoms such as diarrhoea, incontinence and rectal bleeding as the functions of the healthy tissues surrounding the cancer
are disrupted by the radiation.
Typically, the severity of these symptoms is rated on a scale in grades from Grade 0 to Grade 4.
Dr Robert Huddart, Professor of Urological Cancer at the ICR and Consultant in Urological Oncology at The Royal Marsden, who led the study, told Thailand Medical
News, “We hypothesised that using IMRT
would give the best chance of maximising the dose of radiation
which is delivered to the tumours, while minimising the dose of radiation
delivered to healthy cells, reducing the risk of toxic side effects in patients.”
The research findings was published in the journal Clinical Oncology
and was conducted with part-funding from National Institute for Health Research’s Biomedical Research Centre at the Royal Marsden.
Certain of the patients in the study had already received chemotherapy to try to shrink the tumour before beginning radiotherapy
treatment, known as neoadjuvant chemotherapy. This allowed the researchers to assess whether chemotherapy alone, or chemotherapy in conjunction with radiotherapy
provides the best chances for these patients.
A total of 37 patients received IMRT
in this study. Radiotherapy
treatment was targeted at four separate areas ie the whole bladder,
pelvic lymph nodes
, tumour bed and involved lymph nodes. CT scans were used to look at these four areas and plan the radiotherapy
treatment for each patient.
was delivered to patients using IMRT
supported by cone-beam computed tomography imaging, a type of CT scan which allows clinicians to produce a virtual 3D image of the area to be treated.
Upon completion of the course of radiotherapy
, patients were reviewed at 4, 8 and 12 weeks to check for any toxic effects from treatment. Patients were then followed up every six months up to three years, and then annually up to five years.
Though most patients ie between 70.3% and 82.4%, suffered negative side effects, including diarrhoea and increased urinary frequency, most of these were mild to moderate and short-lived resolving in the weeks following treatment.
By twelve months after treatment, the levels of side effects had reduced dramatically. Just 5% of patients were experiencing side effects at the more severe end of the scale – Grades 3 and 4, one year after treatment. A check at four years reported that none of the patients was experiencing side effects at the more severe end of the scale.
It was observed that the five-year overall survival rate was 34%, which is comparable to the survival rate of node-positive bladder cancer
patients who receive chemotherapy and surgery alone.
Dr Huddart added, “This trial shows that delivering IMRT
to the pelvic lymph nodes
is feasible as a part of a treatment plan for patients with node positive bladder cancer
, and patients are able to receive and tolerate appropriate doses of radiation
. More work needs to be done to combine radiotherapy
and chemotherapy to increase the chances of survival and decrease the chances of relapse but these results show that IMRT radiotherapy
is a promising new option for this group of patients.”
Reference: Tan, et al. (2020) The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study. Clinical Oncology DOI: https://doi.org/10.1016/j.clon.2019.07.017